Physician profile
Jonathan D Brewer
NPI 1447226451
$756.67
in general payments reported to CMS, 2019-2025
10 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.29 · 2020: $13.72 · 2022: $48.12 · 2023: $224 · 2024: $260 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.16 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $209.50 | 2019-2024 | Nucala |
| Inspire Medical Systems, INC. | $173.13 | 2024-2025 | Inspire |
| Intuitive Surgical, INC. | $133.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.72 | 2019-2023 | Ofev |
| Insmed, INC. | $49.86 | 2022-2025 | Brinsupri |
| Astrazeneca Pharmaceuticals LP | $43.68 | 2023-2024 | Fasenra, Airsupra |
| United Therapeutics Corporation | $30.98 | 2022-2024 | Tyvaso |
| Zoll Respicardia, INC. | $29.63 | 2023 | Remede System |
| Jazz Pharmaceuticals INC. | $19.71 | 2019 | |
| Amgen INC. | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.